24/7 Market News Snapshot 20 October, 2025 – SiNtx Technologies, Inc. Common Stock (NASDAQ:SINT)
DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:SINT) are discussed in this article.
SINTX Technologies, Inc. (NASDAQ:SINT) is currently experiencing a notable surge in its pre-market trading, with shares priced at $4.53—an impressive rise of approximately 14.39% from the previous close of $3.96. The heightened interest from investors is echoed in the current trading volume, which stands at 1.80 million shares. This trend suggests that SINTX’s stock may be breaking through significant resistance levels, indicating the potential for continued upward momentum. Investors might view this shift as an opportune moment to buy, although vigilance regarding market sentiment and potential volatility in upcoming sessions will be essential for sustaining these gains.
As this bullish market activity unfolds, SINTX has also marked a significant milestone with the recent FDA clearance of its innovative SINAPTIC® Foot & Ankle Osteotomy Wedge System. Set to launch in the first quarter of 2026, this system leverages the company’s proprietary silicon nitride biomaterial alongside specialized implant designs, targeting an expanding reconstructive foot and ankle surgery market projected to reach approximately $4.75–$5.4 billion by 2024.
The SINAPTIC system will come with a sterile, single-use instrument kit aimed at enhancing surgical efficiency and precision. According to Lisa Marie Del Re, Chief Commercial Officer of SINTX, there is a growing demand for non-metal solutions in orthopedics, and this innovation is positioned to meet that need through exceptional performance in foot and ankle reconstruction.
Moreover, the unique properties of the silicon nitride used in the SINAPTIC system—including its ability to promote protein absorption, inhibit bacterial growth, and provide clear imaging compared to metal implants—underscore SINTX’s commitment to advancing orthopedic solutions. Eric Olson, Chairman, President & CEO, describes this FDA clearance as a defining moment, where the company aims to create substantial clinical impact while delivering shareholder value as it prepares for commercialization.